Charles River Laboratories has opened a 60,000 sq. ft. preclinical facility in Shanghai. The site is expected to provide GLP services in the first quarter of 2009.
Through this facility, Charles River will help multinationals and local biopharmaceutical organizations accelerate their drug development programs in China. Services provided will comply with regulatory agencies including the Association for Assessment and Accreditation of Laboratory Animal Care, Canadian Council on Animal Care, China’s State Food and Drug Administration, Organization for Economic Cooperation and Development, and FDA.
“As our clients make their initial forays into China, we are creating a center of excellence that embodies global best practices alongside them,” notes James C. Foster, president, chairman, and CEO. “The same high standards of research, safety, humane care, and good laboratory practices that globally distinguish Charles River are replicated in our Shanghai facility.”
This facility is a result of a joint venture inked in March 2007 with Shanghai BioExplorer. Charles River Preclinical Services Greater China was thus formed, which is majority-owned and controlled by Charles River.